文献速递细菌感染、耐药与抗菌药物

米诺环素联合甲硝唑治疗大环内酯类耐药生殖支原体的疗效与耐受性

Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

在墨尔本性健康中心开展的前瞻性评估中,口服米诺环素100mg联合甲硝唑400mg每日两次共14天,治疗大环内酯类耐药生殖支原体感染(氟喹诺酮类治疗失败或不适用者)的微生物学治愈率为80.8%(95%CI: 71.9-87.8%)。既往接受过多西环素者治愈率为90.3%(n=28/31,95%CI: 74.2-98.0%),未接受者为76.7%(n=56/73,95%CI: 65.4-85.8%),P=0.172。中枢神经系统和胃肠道副作用常见。

要点

  • 米诺环素联合甲硝唑14天方案对大环内酯类耐药生殖支原体的微生物学治愈率为80.8%(95%CI: 71.9-87.8%)。
  • 既往使用多西环素者治愈率90.3%(28/31) vs 未使用者76.7%(56/73),P=0.172。
  • 中枢神经系统和胃肠道副作用常见,临床医生应与患者讨论。

核心结论

  • 米诺环素联合甲硝唑在该队列中治愈了80%的大环内酯类耐药生殖支原体感染。
  • 联合方案前使用多西环素可能提高治愈率,但需更大规模研究证实。
  • 在无替代药物或喹诺酮类禁忌时,该联合方案可能是 promising 的选择。

研究设计与样本

  • 2021年9月至2024年8月在墨尔本性健康中心开展的前瞻性评估。
  • 对象为大环内酯类耐药生殖支原体感染且氟喹诺酮类治疗失败或不适用者。
  • 干预为口服米诺环素100mg联合甲硝唑400mg,每日两次,共14天。
  • 微生物学治愈定义为完成方案后14-90天采用转录介导扩增检测治愈试验(TOC)阴性。

主要发现

  • 总体微生物学治愈率为80.8%(95%CI: 71.9-87.8%)。
  • 既往接受多西环素者治愈率90.3%(n=28/31,95%CI: 74.2-98.0%),未接受者76.7%(n=56/73,95%CI: 65.4-85.8%),P=0.172。
  • 中枢神经系统和胃肠道副作用常见报告。

临床怎么用

  • 对于大环内酯类耐药生殖支原体感染且氟喹诺酮类失败或不适用者,可考虑米诺环素100mg联合甲硝唑400mg每日两次共14天方案。
  • 临床医生应了解并与患者讨论该方案的副作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Curing Mycoplasma genitalium is challenging in the context of rising antimicrobial resistance and limited therapeutic options. There is an urgent need for globally relevant and effective treatment options using readily available and affordable agents. From September 2021 to August 2024 at Melbourne Sexual Health Centre, we prospectively evaluated microbial cure and tolerability of oral minocycline 100 mg combined with metronidazole 400 mg (twice daily for 14 days) for individuals with macrolide-resistant M. genitalium in whom fluroquinolones had failed or were not advised. METHODS: Microbial cure was defined as a negative test of cure (TOC) using transcription-mediated amplification 14-90 days after completing the regimen. The proportion cured and 95% confidence intervals (CIs) were calculated. Data on side effects and adherence were collected at TOC visits. RESULTS: Microbial cure in patients receiving the combination regimen was 80.8% (95% CI: 71.9-87.8%). Cure in those who had received preceding doxycycline was 90.3% (n = 28/31, 95% CI: 74.2-98.0%) compared to 76.7% (n = 56/73, 95% CI: 65.4-85.8%) in those who had not, P = 0.172. Central nervous system and gastrointestinal side effects were commonly reported. CONCLUSIONS: Minocycline with metronidazole cured 80% of macrolide-resistant infections in this cohort. Cure may be enhanced by the use of doxycycline before the combination regimen but larger studies are needed. Given limited options for treating resistant M. genitalium infections, the combined minocycline and metronidazole regimen may represent a promising option where no alternative drugs are available, or quinolones are contraindicated. Clinicians should be aware of and discuss side effects with patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Htaik K, Vodstrcil LA, Plummer EL, et al. Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium. J Antimicrob Chemother. 2025. PMID: 40401482. doi:10.1093/jac/dkaf142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。